Progress on targeting TRAIL's receptor as antitumor strategy

Yaoxue Xuebao

Volumn 44, Issue 12, 2009, Pages 1336-1342

  Chen, Shu Zhen ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Antitumor activity; Apoptosis; Death receptor; TRAIL

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; GPI-LINKED PROTEINS; HUMANS; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 76249083752     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Hou Q. Effect of staurosporine induced apoptosis of MCF7/GFP-Bax stable cell line on Bax translocation from cytosol into mitochondria [J]. Acta Pharm Sin 2008, 43: 378-382.
2. Wiley SR, Schoole YK, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis [J]. Immunity, 1995, 3: 673-682.
3. Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy [J]. Apoptosis, 2002, 7: 449-459.
4. Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them [J]. Drug Resist Updat, 2008: 17-24.
5. Mérino D, Lalaoui N, Morizot A, et al. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2 [J]. Mol Cell Biol, 2006, 16: 7046-7055.
6. Chen S, Liu X, Yue P, et al. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non-small-cell lung cancer cells [J]. Mol Pharmacol, 2007, 72: 1269-1279.
7. Bouralexis S, Findlay DM, Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL [J]. Apoptosis, 2005, 10: 35-51.
8. Bouralexis S, Findlay DM, Atkins GJ, et al. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy [J]. Br J Cancer, 2003, 89: 206-214.
9. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors [J]. Cell Death Differ, 2003, 10: 66-75.
10. Horak P, Pils D, Haller G, et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer [J]. Mol Cancer Res, 2005, 3: 335-343.
11. Spierings DC, de Vries EG, Timens W, et al. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors [J]. Clin Cancer Res, 2003, 9: 3397-3405.
12. Koornstra JJ, Kleibeuker JH, van Geelen CM, et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas [J]. J Pathol, 2003, 200: 327-335.
13. McCarthy MM, Sznol M, DiVito KA, et al. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer [J]. Clin Cancer Res, 2005, 11: 5188-5194.
14. Shivapurkar N, Toyooka S, Toyooka KO, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types [J]. Int J Cancer, 2004, 109: 786-792.
15. Cretney E, Takeda K, Smyth MJ. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway [J]. Int J Biochem Cell Biol, 2007, 39: 280-286.
16. Koschny R, Walczak H, Ganten T. The promise of TRAIL-potential and risks of a novel anticancer therapy [J]. J Mol Med, 2007, 85: 923-935.
17. El-Zawahry A, Lu P, White SJ, et al. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL [J]. Cancer Gene Ther, 2006, 13: 281-289.
18. Jeong M, Kwon YS, Park SH, et al. Possible novel therapy for malignant gliomas with secretable trimeric TRAIL [J]. PLoS One, 2009, 4: e4545.
19. Guan B, Yue P, Clayman GL, et al. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene [J]. J Cell Physiol, 2001, 188: 98-105.
20. Yoo J, Park SS, Lee YJ. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells [J]. J Cell Biochem, 2008, 104: 1636-1646.
21. Seol JW, Chaudhari AA, Lee YJ, et al. Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis [J]. Oncol Rep, 2007, 18: 523-529.
22. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy [J]. Nat Rev Cancer, 2008, 8: 782-798.
23. Liu X, Yue P, Chen S, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells [J]. Cancer Res, 2007, 67: 4981-4988.
24. Liu X, Yue P, Schönthal AH, et al. Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells [J]. Cancer Res, 2006, 66: 11115-11119.
25. Shi P, Chen WW, Hu XY, et al. Curcumin up-regulates the expression of maspin gene in prostate cancer cell line LNCaP [J]. Acta Pharm Sin 2006, 41: 1152-1156.
26. Reuter S, Eifes S, Dicato M, et al. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells [J]. Biochem Pharmacol, 2008, 76: 1340-1351.
27. Nagane M, Pan G, Weddle JJ, et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo [J]. Cancer Res, 2000, 60: 847-853.
28. Takeda K, Yamaguchi N, Akiba H, et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy [J]. J Exp Med, 2004, 199: 437-448.
29. Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy [J]. Nat Med, 2006, 12: 693-698.